国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity

第一作者:Bin Dai

通讯作者:LIWEI ZHANG

tumorigenicity

基本信息

  • 负责人:Bin Dai
  • 数据来源: OTHERS
  • 论文编号:OTHERS20190324
  • 发表时间:2015-11-01

2015-11-01

已发表文章

发表杂志:Oncology Reports

发表类型: Oncology Reports

影响因子(IF): 3.906

PMID: 26328527 Pubmed原文链接 全文下载

主要研究背景及目的

方法

Here, we determined the expression of SMYD3 and assessed its clinical significance in human glioma.

结论

These results showed that SMYD3 is overexpressed in human glioma and contributes to glioma tumorigenicity through p53. Therefore, SMYD3 may be a new potential therapeutic target for human malignant glioma.

主要结果

We found that SMYD3 was overexpressed in human glioma but not in normal brain tissue. The level of SMYD3 protein expression in human glioma tissues was directly correlated with the glioma grade. The level of SMYD3 protein expression in human glioma tissues was inversely correlated with patient survival. Enforced SMYD3 expression promoted glioma LN-18 cell proliferation. Inhibition of SMYD3 expression in glioma T98G cells suppressed their anchorage‑independent growth in vitro and tumorigenicity in vivo. Furthermore, we found that SMYD3 regulated the expression of p53 protein, which is essential in SMYD3‑induced cell growth in glioma cells.